These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16837820)

  • 21. Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy.
    Tzaida O; Gogas H; Dafni U; Kyroudi A; Papaspyrou I; Kyriakou V; Malamou-Mitsi V; Alamani M; Skopa C; Kostopoulos I; Kastritis E; Pectasides D; Briasoulis E; Kalofonos HP; Aravantinos G; Fountzilas G; Arapantoni-Dadioti P
    Oncology; 2007; 72(5-6):388-96. PubMed ID: 18187961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
    Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
    Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
    Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
    Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
    Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
    Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells.
    Cano-Soldado P; Molina-Arcas M; Algueró B; Larráyoz I; Lostao MP; Grandas A; Casado FJ; Pastor-Anglada M
    Biochem Pharmacol; 2008 Feb; 75(3):639-48. PubMed ID: 18053967
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
    Gruber G; Bonetti M; Nasi ML; Price KN; Castiglione-Gertsch M; Rudenstam CM; Holmberg SB; Lindtner J; Golouh R; Collins J; Crivellari D; Carbone A; Thürlimann B; Simoncini E; Fey MF; Gelber RD; Coates AS; Goldhirsch A;
    J Clin Oncol; 2005 Oct; 23(28):7089-97. PubMed ID: 16192592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.
    Parulekar WR; Day AG; Ottaway JA; Shepherd LE; Trudeau ME; Bramwell V; Levine M; Pritchard KI;
    J Clin Oncol; 2005 Sep; 23(25):6002-8. PubMed ID: 16135468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
    Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
    Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
    Muss HB; Thor AD; Berry DA; Kute T; Liu ET; Koerner F; Cirrincione CT; Budman DR; Wood WC; Barcos M
    N Engl J Med; 1994 May; 330(18):1260-6. PubMed ID: 7908410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
    Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
    Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer.
    Sonnenblick A; Uziely B; Nechushtan H; Kadouri L; Galun E; Axelrod JH; Katz D; Daum H; Hamburger T; Maly B; Allweis TM; Peretz T
    Breast Cancer Res Treat; 2013 Apr; 138(2):407-13. PubMed ID: 23446809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression.
    Jacquemier J; Penault-Llorca F; Viens P; Houvenaeghel G; Hassoun J; Torrente M; Adélaïde J; Birnbaum D
    Anticancer Res; 1994; 14(6B):2773-8. PubMed ID: 7872717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/cyclophosphamide therapy using a 70-gene classifier for breast cancers.
    Naoi Y; Kishi K; Tanei T; Tsunashima R; Tominaga N; Baba Y; Kim SJ; Taguchi T; Tamaki Y; Noguchi S
    Cancer; 2011 Aug; 117(16):3682-90. PubMed ID: 21305539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy.
    Miscoria M; Tonetto F; Deroma L; Machin P; Di Loreto C; Driol P; Minisini AM; Russo S; Andreetta C; Mansutti M; Damante G; Fasola G; Puglisi F
    Anticancer Drugs; 2012 Mar; 23(3):326-34. PubMed ID: 22129512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.